Excessive Gluconeogenesis Causes the Hepatic Insulin Resistance Paradox and Its Sequelae
Overview
Authors
Affiliations
Background: Hepatic insulin signaling suppresses gluconeogenesis but promotes de novo lipid synthesis. Paradoxically, hepatic insulin resistance (HIR) enhances both gluconeogenesis and de novo lipid synthesis. Elucidation of the etiology of this paradox, which participates in the pathogenesis of non-alcoholic fatty liver disease (NAFLD), cardiovascular disease, the metabolic syndrome and hepatocellular carcinoma, has not been fully achieved.
Scope Of Review: This article briefly outlines the previously proposed hypotheses on the etiology of the HIR paradox. It then discusses literature consistent with an alternative hypothesis that excessive gluconeogenesis, the direct effect of HIR, is responsible for the aberrant lipogenesis. The mechanisms involved therein are explained, involving de novo synthesis of fructose and uric acid, promotion of glutamine anaplerosis, and induction of glucagon resistance. Thus, gluconeogenesis via lipogenesis promotes hepatic steatosis, a component of NAFLD, and dyslipidemia. Gluconeogenesis-centred mechanisms for the progression of NAFLD from simple steatosis to non-alcoholic steatohepatitis (NASH) and fibrosis are suggested. That NAFLD often precedes and predicts type 2 diabetes is explained by the ability of lipogenesis to cushion against blood glucose dysregulation in the earlier stages of NAFLD.
Major Conclusions: HIR-induced excessive gluconeogenesis is a major cause of the HIR paradox and its sequelae. Such involvement of gluconeogenesis in lipid synthesis rationalizes the fact that several types of antidiabetic drugs ameliorate NAFLD. Thus, dietary, lifestyle and pharmacological targeting of HIR and hepatic gluconeogenesis may be a most viable approach for the prevention and management of the HIR-associated network of diseases.
Lai P, Miao G, Zhao Y, Han Y, Li Y, Liu Y Nat Commun. 2025; 16(1):2430.
PMID: 40069146 PMC: 11897346. DOI: 10.1038/s41467-025-57585-0.
Harnessing the FOXO-SIRT1 axis: insights into cellular stress, metabolism, and aging.
Gupta S, Afzal M, Agrawal N, Almalki W, Rana M, Gangola S Biogerontology. 2025; 26(2):65.
PMID: 40011269 DOI: 10.1007/s10522-025-10207-0.
Blazewicz A, Kielbus M, Skorzynska-Dziduszko K, Grabrucker A, Jonklaas J, Sosnowski P Molecules. 2024; 29(21).
PMID: 39519809 PMC: 11547455. DOI: 10.3390/molecules29215169.
Computational Strategies for Assessing Adverse Outcome Pathways: Hepatic Steatosis as a Case Study.
Ortega-Vallbona R, Palomino-Schatzlein M, Tolosa L, Benfenati E, Ecker G, Gozalbes R Int J Mol Sci. 2024; 25(20).
PMID: 39456937 PMC: 11508863. DOI: 10.3390/ijms252011154.
Associations of Amino Acids with the Risk of Prediabetes: A Case-Control Study from Kazakhstan.
Nurtazina A, Voitsekhovskiy I, Kanapiyanov B, Toishimanov M, Dautov D, Karibayev K J Pers Med. 2024; 14(10).
PMID: 39452573 PMC: 11509736. DOI: 10.3390/jpm14101067.